GSK enters into partnership with Propeller Health to develop digital sensors for inhalers

US based Propeller Health, provider of a digital health solution for improving outcomes in asthma and chronic obstructive pulmonary disease (COPD), will be collaborating with GSK to develop a new sensor for GSK’s ElliptaTM inhaler for use in certain clinical studies in asthma and COPD.

In the studies, the sensor will automatically collect and record data on the inhaler’s usage and will wirelessly transmit the information to a central data repository for analysis by GSK’s clinical researchers.

The sensor technology will be used to provide greater insights on how patients adhere to prescription advice and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.

GSK retains an option to negotiate exclusive commercialization rights to the sensor for use with its marketed portfolio of respiratory medicines administered using the Ellipta inhaler. 

Dave Allen, Senior Vice President of Respiratory R&D at GSK, said, “We continue to find new and better ways to conduct clinical trials by exploring novel patient centred outcomes through strategic collaborations. Using innovative sensor technology to improve the quality of adherence data collected during our studies will advance our understanding of disease and inform our decision-making in the development of new medicines.”

The Propeller platform has been used by patients in over 35 commercial programs across the US, including major healthcare systems, payers, employers and other commercial partners.

To date, the Propeller platform has received US FDA 510(k) class II clearance to measure and improve medication adherence, help predict exacerbations, and help reduce the frequency of symptoms and exacerbations in asthma and COPD.